Results 201 to 210 of about 90,574 (284)

Classification of tau status with machine learning models in amyloid‐positive cohorts

open access: yesAlzheimer's &Dementia, Volume 22, Issue 8, August 2026.
Abstract INTRODUCTION Although tau positron emission tomography (PET) imaging is effective for staging tau pathology, it is limited clinically by cost and availability. Machine learning models based on magnetic resonance imaging (MRI)– and amyloid PET–derived features may serve as useful screening tools for tau pathology.
Yun‐Chi Lin   +4 more
wiley   +1 more source

Endogenous melatonin partial metabolic clearance as a potential endogenous marker of CYP1A2 activity

open access: yesBritish Journal of Clinical Pharmacology, Volume 92, Issue 8, Page 2899-2908, August 2026.
Aims Cytochrome P450 1A2 (CYP1A2) exhibits substantial interindividual variability, necessitating appropriate phenotyping strategies for personalized pharmacotherapy. This study evaluated endogenous melatonin partial metabolic clearance (CLm(MEL)), calculated from urinary 6‐hydroxymelatonin (6‐O‐MEL) excretion and plasma melatonin (MEL) exposure, as a ...
Akitomo Yokokawa   +5 more
wiley   +1 more source

Biomarker‐Based Prediction of OATP1B1 Activity in Clinical Routine—Investigating Coproporphyrins as Markers for Drug–Drug–Gene Interactions

open access: yesClinical Pharmacology &Therapeutics, Volume 120, Issue 2, Page 492-500, August 2026.
Coproporphyrin I (CPI) is an established endogenous biomarker for detecting drug–drug interactions (DDIs) involving the hepatic uptake transporter Organic Anion Transporting Polypeptide 1B1 (OATP1B1, gene SLCO1B1). While CPI has been extensively studied in healthy volunteers using controlled pre‐ and post‐OATP1B1‐inhibitor sampling, its applicability ...
Leila Potzel   +9 more
wiley   +1 more source

Anexos

open access: yesOASIS, 2008
Revista OASIS
doaj  

A Review of Lifestyle Interventions Provided as an Adjunct to Obesity Management Medications

open access: yesObesity Science &Practice, Volume 12, Issue 4, August 2026.
ABSTRACT Objective This review synthesized the components of lifestyle interventions that have been provided in Phase 3 trials of obesity management medications (OMMs). Methods PubMed, CINAHL, and EMBASE were searched for Phase 3 clinical trials published from inception to February 2026 that tested FDA‐approved OMMs.
Ariana M. Chao   +5 more
wiley   +1 more source

Anexos

open access: yesOASIS, 1996
Revistas OASIS
doaj  

Home - About - Disclaimer - Privacy